Short-term outcomes of Forrest IIB peptic ulcer bleeding treated with high-dose intravenous nexium following endoscopic intervention and associated factors

Objective: To describe the short-term outcomes of Forrest IIB peptic ulcer bleeding treated with high-dose intravenous Nexium following endoscopic intervention, and to assess associated factors. Subjects and method: A prospective cross-sectional study was conducted on 52 patients with Forrest IIB peptic ulcer bleeding treated with high-dose intravenous Nexium following endoscopic intervention between January 2020 and December 2024. Result: This prospective descriptive study included 52 patients with upper gastrointestinal bleeding due to Forrest IIB peptic ulcers, aiming to evaluate clinical characteristics and treatment outcomes. The mean age was 59.6 ± 17.1 years, with a male-to-female ratio of 2.25. A history of NSAID/corticosteroid use was reported in 46.2% of patients. The most common symptoms were hematemesis/melena (76.9%) and epigastric pain (69.2%). The initial hemostasis rate was 96.2%, rebleeding within 7 days occurred in 3.8%, and no 30-day mortality was observed. Univariate regression analysis identified a history of NSAID/corticosteroid use and a Blatchford score ≥10 as risk factors for treatment failure. Conclusion: Forrest IIB ulcer bleeding remains at risk of rebleeding after endoscopic therapy. A history of NSAID/corticosteroid use and a high Blatchford score are predictors of treatment failure.